(CDAX, Industrial Goods & Services)



Buy		Value DCF:
EUR 4.00	(EUR 3.40)	Mark
Price	EUR 3.19	Marke No. of
Upside	25.4 %	EV: Freefl Ø Tra

Value Indicators: DCF:	EUR 4.01
Market Snapshot:	EUR m
Market cap:	49.3
No. of shares (m):	15.5
EV:	87.5
Freefloat MC:	25.0
Ø Trad. Vol. (30d):	36.55 th

Share data:	
Bloomberg:	FPH GR
Reuters:	FPHG
ISIN:	DE000FPH9000
Shareholders:	

ISIN:	DE000FPH9000
Shareholders:	
Freefloat	50.7 %
Obotritia Capital	28.0 %
Active Ownership Fund	9.5 %
SALTARAX GmbH	5.0 %

Description:Manufacturer of franking machines

and provider of mail services.

Risk Profile (WRe):	2020e
Beta:	1.8
Price / Book:	1.5 x
Equity Ratio:	18 %
Net Fin. Debt / EBITDA:	0.6 x
Net Debt / EBITDA:	1.4 x

Very strong Q1

Figures Q1/20	020:						
in EUR m	Q1/20	Q1/20e	Q1/19	yoy	2020e	2019	yoy
Sales	57.0	53.0	52.1	9.4%	192.4	209.1	-8.0%
EBITDA	8.0	7.0	6.9	14.9%	27.9	33.3	-16.3%
margin	14.0%	14.8%	13.3%		14.5%	15.9%	

Comment on Figures:

- Francotyp-Postalia AG announced the key data for the first quarter yesterday, May 26, 2020. Sales and earnings were significantly above expectations (WRe).
- The publication of the final quarterly report is scheduled for May 28, 2020.

The strong figures were especially driven by significant growth in the Mail Services segment and in the core business of franking machines. The COVID-19 pandemic meant business in the Software/Digital product area remained rather weak. Apart from this, the company is strictly controlling its cost structure and the strategic adjustments of the recent years are showing success.

Overall, the pandemic continues to be a major factor of uncertainty, especially as regards the forecast for the current year. In principle, weak economic development can also have a negative (long-term) impact on the customer base (see also our publication dated April 6, 2020).

Against the background of the excellent first quarter and considering that the burden from the COVID-19 pandemic is proving rather moderate in the German core market, the forecasts are now being adjusted upwards again after an initial significant negative adjustment (WRe).

Based on the increased forecasts and the adjustment of the risk parameter (beta) used in the DCF model, the price target is now significantly higher again. With a target price of EUR 4.00 (3.40), the share continues to be rated Buy.

Changes in E	stimates:					
FY End: 31.12. in EUR m	2020e (old)	+ / -	2021e (old)	+/-	2022e (old)	+ / -
Sales	188.1	2.3 %	193.7	2.3 %	n.a.	n.m.
EBITDA	23.5	18.6 %	29.1	2.3 %	n.a.	n.m.
EBIT	1.0	432.6 %	6.1	10.9 %	n.a.	n.m.
EPS	0.03	633.3 %	0.25	8.0 %	n.a.	n.m.

Comment on Changes:

- The basis of the new earnings estimate is slightly higher sales than the original forecast (WRe).
- Together with a better cost structure, this leads to the positive adjustments shown.
- The high percentage deviation in the current year is caused by a base effect.




Rel. Performance vs CDAX:	
1 month:	0.8 %
6 months:	4.2 %
Year to date:	6.6 %
Trailing 12 months:	0.7 %
Company events:	
28.05.20	Q1
17.06.20	AGM
27.08.20	Q2
16.11.20	Q3

FY End: 31.12. in EUR m	CAGR (19-22e)	2016	2017	2018	2019	2020e	2021e	2022e
Sales	-0.8 %	203.0	206.3	204.2	209.1	192.4	198.1	204.1
Change Sales yoy		6.2 %	1.7 %	-1.0 %	2.4 %	-8.0 %	3.0 %	3.0 %
Gross profit margin		58.1 %	55.6 %	57.0 %	60.3 %	59.0 %	58.5 %	58.5 %
EBITDA	-2.8 %	27.2	26.3	17.1	33.3	27.9	29.7	30.6
Margin		13.4 %	12.8 %	8.4 %	15.9 %	14.5 %	15.0 %	15.0 %
EBIT	8.9 %	9.7	7.3	-0.3	5.9	5.4	6.7	7.6
Margin		4.8 %	3.5 %	-0.1 %	2.8 %	2.8 %	3.4 %	3.7 %
Net income	43.6 %	5.9	4.6	0.9	1.7	3.5	4.4	5.0
EPS	41.3 %	0.36	0.29	0.06	0.11	0.22	0.27	0.31
EPS adj.	41.3 %	0.36	0.29	0.06	0.11	0.22	0.27	0.31
DPS	60.5 %	0.16	0.12	0.03	0.03	0.09	0.11	0.12
Dividend Yield		3.8 %	2.3 %	0.8 %	0.9 %	2.8 %	3.4 %	3.9 %
FCFPS		0.28	0.36	0.38	0.17	0.22	0.25	0.29
FCF / Market cap		6.7 %	6.9 %	10.1 %	5.0 %	7.0 %	7.9 %	9.1 %
EV / Sales		0.5 x	0.5 x	0.4 x	0.5 x	0.5 x	0.4 x	0.4 x
EV / EBITDA		3.6 x	4.2 x	5.0 x	2.9 x	3.2 x	3.0 x	2.8 x
EV / EBIT		9.9 x	15.1 x	n.a.	16.3 x	16.6 x	13.1 x	11.3 x
P/E		11.7 x	17.9 x	62.6 x	31.5 x	14.5 x	11.8 x	10.3 x
P / E adj.		11.7 x	17.9 x	62.6 x	31.5 x	14.5 x	11.8 x	10.3 x
FCF Potential Yield		12.0 %	11.2 %	2.2 %	10.0 %	13.3 %	15.9 %	16.5 %
Net Debt		28.4	25.2	24.6	40.3	38.2	36.4	34.4
ROCE (NOPAT)		9.5 %	7.7 %	n.a.	2.6 %	5.0 %	6.2 %	6.9 %
Guidance:	n.a.							

+49 40 309537-120






Company Background

- Francotyp Postalia Holding AG, headquarted in Berlin, is a globally-active supplier of products and services for the postal market.
- The company was formed in 1983 with the merger of Francotyp (founded 1923) and Postalia (founded 1938) and has thus more than 80 years of experience in the postal market.
- In the course of the liberalisation of the postal market, the FP group transformed itself from a producer of franking machines to a solutions provider for mail management and processing.
- Franking and inserting machines are still the core business activity.
- With new solutions e.g. In the field of IoT and electronic signature, the company strategically expanded its portfolio.

Competitive Quality

- Focusing on customers with low to medium postal needs, Francotyp Postalia caters for two stable segments in the generally difficult market for franking machines.
- The 45% market share in the German market for franking machines demonstrates its reputation as the market leader in Germany based on the following distinguishing characteristics:
- established customer relationships and 80 years of experience in the German market with knowledge of customer demands and an efficient service network with rapid reaction times.
- The high proportion (about three-quarters) of recurring revenues as a share of total revenue underlines the successful transformation of the competitive quality into a high company quality.
- For new market entrants, Francotyp Postalia's existing customer base is an unachievable target and the franking machines niche is unattractive.





DCF model														
	Detaile	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	
Sales	192.4	198.1	204.1	210.2	216.5	223.0	229.7	236.6	243.7	251.0	258.5	266.3	274.3	
Sales change	-8.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	1.0 %
EBIT	5.4	6.7	7.6	10.5	13.0	13.4	13.8	14.2	14.6	15.1	15.5	16.0	16.5	
EBIT-margin	2.8 %	3.4 %	3.7 %	5.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	
Tax rate (EBT)	32.0 %	32.0 %	32.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	
NOPAT	3.7	4.6	5.2	7.0	8.7	9.0	9.2	9.5	9.8	10.1	10.4	10.7	11.0	
Depreciation	22.5	23.0	23.0	18.9	19.5	20.1	20.7	21.3	21.9	22.6	23.3	24.0	24.7	
in % of Sales	11.7 %	11.6 %	11.3 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	
Changes in provisions	1.0	1.1	1.1	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	
Change in Liquidity from														
- Working Capital	-0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	
- Capex	26.0	26.0	26.0	21.0	21.7	20.1	20.7	21.3	21.9	22.6	23.3	24.0	24.7	
Capex in % of Sales	13.5 %	13.1 %	12.7 %	10.0 %	10.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	1.8	2.2	2.8	4.7	6.3	8.7	9.0	9.2	9.5	9.8	10.0	10.3	10.6	10
PV of FCF	1.7	1.9	2.3	3.5	4.3	5.4	5.1	4.8	4.5	4.3	4.0	3.8	3.6	43
share of PVs		6.39 %						46.96	6 %					46.65 %

Model parameter			Valuation (m)								
Derivation of WACC:		Derivation of Beta:		Present values 2032e	49						
				Terminal Value	43						
Debt ratio	25.00 %	Financial Strength	1.80	Financial liabilities	50						
Cost of debt (after tax)	2.1 %	Liquidity (share)	1.80	Pension liabilities	21						
Market return	7.00 %	Cyclicality	1.80	Hybrid capital	0						
Risk free rate	1.50 %	Transparency	Transparency 1.80		0						
		Others	1.80	Market val. of investments	0						
				Liquidity	41	No. of shares (m)	15.5				
WACC	9.08 %	Beta 1.80		Equity Value	62	Value per share (EUR)	4.01				

Sens	Sensitivity Value per Share (EUR)																
Terminal Growth Delta EBIT-margin																	
Beta	WACC	0.25 %	0.50 %	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
2.04	10.1 %	3.07	3.12	3.17	3.23	3.30	3.36	3.43	2.04	10.1 %	1.58	2.13	2.68	3.23	3.79	4.34	4.89
1.92	9.6 %	3.40	3.46	3.53	3.60	3.67	3.75	3.83	1.92	9.6 %	1.84	2.43	3.01	3.60	4.18	4.77	5.35
1.86	9.3 %	3.58	3.65	3.72	3.80	3.88	3.96	4.06	1.86	9.3 %	1.99	2.59	3.19	3.80	4.40	5.00	5.60
1.80	9.1 %	3.77	3.84	3.92	4.01	4.10	4.19	4.29	1.80	9.1 %	2.14	2.76	3.39	4.01	4.63	5.25	5.87
1.74	8.8 %	3.97	4.05	4.14	4.23	4.33	4.43	4.55	1.74	8.8 %	2.31	2.95	3.59	4.23	4.87	5.52	6.16
1.68	8.6 %	4.19	4.28	4.37	4.47	4.58	4.69	4.82	1.68	8.6 %	2.48	3.15	3.81	4.47	5.14	5.80	6.46
1.56	8.1 %	4.66	4.77	4.88	5.01	5.14	5.28	5.43	1.56	8.1 %	2.87	3.58	4.29	5.01	5.72	6.43	7.14

[•] Francotyp generates high steady cash flows in a normal business year.




Valuation							
	2016	2017	2018	2019	2020e	2021e	2022e
Price / Book	1.9 x	2.5 x	1.8 x	1.7 x	1.5 x	1.4 x	1.2 x
Book value per share ex intangibles	0.07	-0.09	-0.46	-0.42	-0.67	-0.91	-1.14
EV / Sales	0.5 x	0.5 x	0.4 x	0.5 x	0.5 x	0.4 x	0.4 x
EV / EBITDA	3.6 x	4.2 x	5.0 x	2.9 x	3.2 x	3.0 x	2.8 x
EV / EBIT	9.9 x	15.1 x	n.a.	16.3 x	16.6 x	13.1 x	11.3 x
EV / EBIT adj.*	9.9 x	15.1 x	n.a.	16.3 x	16.6 x	13.1 x	11.3 x
P/FCF	14.9 x	14.6 x	9.9 x	20.1 x	14.2 x	12.7 x	11.0 x
P/E	11.7 x	17.9 x	62.6 x	31.5 x	14.5 x	11.8 x	10.3 x
P / E adj.*	11.7 x	17.9 x	62.6 x	31.5 x	14.5 x	11.8 x	10.3 x
Dividend Yield	3.8 %	2.3 %	0.8 %	0.9 %	2.8 %	3.4 %	3.9 %
FCF Potential Yield (on market EV)	12.0 %	11.2 %	2.2 %	10.0 %	13.3 %	15.9 %	16.5 %
*Adjustments made for: -							



Consolidated profit & loss							
In EUR m	2016	2017	2018	2019	2020e	2021e	20226
Sales	203.0	206.3	204.2	209.1	192.4	198.1	204.1
Change Sales yoy	6.2 %	1.7 %	-1.0 %	2.4 %	-8.0 %	3.0 %	3.0 %
Increase / decrease in inventory	0.2	0.5	-0.3	0.0	0.0	0.0	0.0
Own work capitalised	11.4	10.8	14.1	18.6	13.5	12.9	13.3
Total Sales	214.5	217.7	218.0	227.6	205.8	211.0	217.3
Material expenses	96.5	102.9	101.6	101.6	92.3	95.1	98.0
Gross profit	118.0	114.8	116.3	126.0	113.5	115.9	119.4
Gross profit margin	58.1 %	<i>55.6</i> %	57.0 %	60.3 %	59.0 %	58.5 %	58.5 %
Personnel expenses	57.4	59.2	64.7	60.2	53.9	55.5	57.1
Other operating income	3.8	4.8	1.9	2.9	1.0	1.0	1.0
Other operating expenses	37.1	34.1	36.4	35.4	32.7	31.7	32.7
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	27.2	26.3	17.1	33.3	27.9	29.7	30.6
Margin	13.4 %	12.8 %	8.4 %	15.9 %	14.5 %	15.0 %	15.0 %
Depreciation of fixed assets	17.5	19.1	17.3	27.4	22.5	23.0	23.0
EBITA	9.7	7.3	-0.3	5.9	5.4	6.7	7.6
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	9.7	7.3	-0.3	5.9	5.4	6.7	7.6
Margin	4.8 %	3.5 %	-0.1 %	2.8 %	2.8 %	3.4 %	3.7 %
EBIT adj.	9.7	7.3	-0.3	5.9	5.4	6.7	7.6
Interest income	1.3	2.1	2.8	2.2	0.8	0.8	0.8
Interest expenses	1.6	1.9	1.4	1.8	0.3	0.3	0.3
Other financial income (loss)	0.1	-0.4	0.1	-0.3	-0.7	-0.7	-0.7
EBT	9.6	7.1	1.3	5.9	5.2	6.5	7.4
Margin	4.7 %	3.4 %	0.6 %	2.8 %	2.7 %	3.3 %	3.6 %
Total taxes	3.4	2.4	0.4	4.2	1.7	2.1	2.4
Net income from continuing operations	6.2	4.6	0.9	1.7	3.5	4.4	5.0
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	6.2	4.6	0.9	1.7	3.5	4.4	5.0
Minority interest	0.3	0.0	0.0	0.0	0.0	0.0	0.0
Net income	5.9	4.6	0.9	1.7	3.5	4.4	5.0
Margin	2.9 %	2.3 %	0.4 %	0.8 %	1.8 %	2.2 %	2.5 %
Number of shares, average	16.2	16.2	16.2	16.2	16.2	16.2	16.2
EPS	0.36	0.29	0.06	0.11	0.22	0.27	0.31
EPS adj.	0.36	0.29	0.06	0.11	0.22	0.27	0.31

Guidance: n.a.


Financial Ratios							
	2016	2017	2018	2019	2020e	2021e	2022e
Total Operating Costs / Sales	92.3 %	92.8 %	98.4 %	92.9 %	92.5 %	91.5 %	91.5 %
Operating Leverage	1.3 x	-15.3 x	n.a.	n.a.	1.1 x	8.2 x	4.4 x
EBITDA / Interest expenses	17.4 x	13.8 x	12.3 x	18.5 x	93.0 x	99.1 x	102.0 x
Tax rate (EBT)	35.5 %	34.3 %	28.4 %	71.3 %	32.0 %	32.0 %	32.0 %
Dividend Payout Ratio	41.7 %	41.7 %	54.1 %	28.4 %	40.3 %	39.4 %	39.8 %
Sales per Employee	170,997	170,431	165,358	165,992	149,718	151,186	152,668





Consolidated balance sheet							
In EUR m	2016	2017	2018	2019	2020e	2021e	20226
Assets							
Goodwill and other intangible assets	34.9	35.1	40.8	38.8	45.8	52.8	59.8
thereof other intangible assets	26.4	26.7	30.3	34.1	41.1	48.1	55.1
thereof Goodwill	8.5	8.5	10.4	4.6	4.6	4.6	4.6
Property, plant and equipment	39.3	31.8	29.9	29.2	25.7	21.7	17.7
Financial assets	9.7	11.6	13.4	18.1	18.1	18.1	18.1
Other long-term assets	0.0	0.0	0.0	11.2	11.2	11.2	11.2
Fixed assets	83.9	78.5	84.1	97.3	100.8	103.8	106.8
Inventories	11.2	10.6	11.2	12.4	11.4	11.7	12.1
Accounts receivable	19.0	19.5	19.0	18.1	17.4	17.9	18.5
Liquid assets	27.1	34.9	30.9	30.5	33.7	36.5	39.7
Other short-term assets	26.2	27.1	21.6	28.0	28.0	28.0	28.0
Current assets	83.4	92.1	82.7	89.0	90.5	94.2	98.2
Total Assets	167.3	170.6	166.7	186.3	191.2	197.9	204.9
Liabilities and shareholders' equity							
Subscribed capital	16.2	16.3	16.3	16.3	16.3	16.3	16.3
Capital reserve	34.6	34.8	34.7	34.7	34.7	34.7	34.7
Retained earnings	0.0	0.0	0.0	0.0	-19.6	-17.4	-14.7
Other equity components	-14.9	-17.4	-17.7	-19.0	3.5	4.4	5.0
Shareholders' equity	35.9	33.7	33.3	32.0	34.9	38.1	41.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	35.9	33.7	33.3	32.0	34.9	38.1	41.4
Provisions	18.0	17.7	17.6	24.0	25.0	26.1	27.2
thereof provisions for pensions and similar obligations	17.1	16.5	16.2	20.6	21.6	22.7	23.8
Financial liabilities (total)	38.4	43.6	39.3	50.2	50.2	50.2	50.2
thereof short-term financial liabilities	0.9	0.4	0.2	4.1	4.1	4.1	4.1
Accounts payable	10.6	11.2	14.0	14.6	13.4	13.8	14.2
Other liabilities	64.3	64.5	62.6	65.5	67.6	69.7	71.8
Liabilities	131.4	137.0	133.4	154.3	156.2	159.8	163.5
Total liabilities and shareholders' equity	167.3	170.6	166.7	186.3	191.2	197.9	204.9

Financial Ratios							
	2016	2017	2018	2019	2020e	2021e	2022e
Efficiency of Capital Employment							
Operating Assets Turnover	3.4 x	4.1 x	4.4 x	4.6 x	4.7 x	5.3 x	6.0 x
Capital Employed Turnover	3.2 x	3.5 x	3.5 x	2.9 x	2.6 x	2.7 x	2.7 x
ROA	7.0 %	5.9 %	1.1 %	1.8 %	3.5 %	4.3 %	4.7 %
Return on Capital							
ROCE (NOPAT)	9.5 %	7.7 %	n.a.	2.6 %	5.0 %	6.2 %	6.9 %
ROE	16.8 %	13.4 %	2.7 %	5.2 %	10.5 %	12.1 %	12.7 %
Adj. ROE	16.8 %	13.4 %	2.7 %	5.2 %	10.5 %	12.1 %	12.7 %
Balance sheet quality							
Net Debt	28.4	25.2	24.6	40.3	38.2	36.4	34.4
Net Financial Debt	11.4	8.6	8.4	19.7	16.5	13.7	10.6
Net Gearing	79.1 %	74.7 %	73.9 %	125.9 %	109.2 %	95.6 %	83.1 %
Net Fin. Debt / EBITDA	41.8 %	32.8 %	49.1 %	59.3 %	59.3 %	46.2 %	34.6 %
Book Value / Share	2.2	2.1	2.1	2.0	2.2	2.4	2.6
Book value per share ex intangibles	0.1	-0.1	-0.5	-0.4	-0.7	-0.9	-1.1




Source: Warburg Research Source: Warburg Research



Consolidated cash flow statement							
In EUR m	2016	2017	2018	2019	2020e	2021e	2022e
Net income	5.9	4.6	0.9	1.7	3.5	4.4	5.0
Depreciation of fixed assets	17.5	19.1	17.3	27.4	22.5	23.0	23.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	1.6	-0.5	-0.3	4.4	1.0	1.1	1.1
Other non-cash income and expenses	0.0	0.0	2.0	0.0	2.0	2.0	2.0
Cash Flow before NWC change	24.9	23.2	19.9	33.5	29.1	30.5	31.2
Increase / decrease in inventory	0.5	0.6	-0.6	-1.2	1.0	-0.3	-0.4
Increase / decrease in accounts receivable	-2.0	-0.6	0.6	0.8	8.0	-0.5	-0.5
Increase / decrease in accounts payable	8.0	0.6	2.8	0.6	-1.2	0.4	0.4
Increase / decrease in other working capital positions	-2.0	-2.5	1.5	-10.7	0.0	0.0	0.0
Increase / decrease in working capital (total)	-2.8	-1.9	4.3	-10.4	0.6	-0.5	-0.5
Net cash provided by operating activities [1]	22.2	21.3	24.2	23.1	29.6	30.1	30.7
Investments in intangible assets	-6.7	-6.9	-9.0	-13.8	-7.0	-7.0	-7.0
Investments in property, plant and equipment	-15.3	-8.6	-9.0	-6.5	-19.0	-19.0	-19.0
Payments for acquisitions	0.0	0.0	-3.5	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.3	-1.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	-17.6	-15.5	-21.2	-21.4	-26.0	-26.0	-26.0
Change in financial liabilities	4.5	4.5	-4.3	11.0	0.0	0.0	0.0
Dividends paid	-2.6	-0.8	-1.9	-0.5	-0.4	-1.3	-1.5
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-2.6	-2.6	-0.2	-15.2	0.0	0.0	0.0
Net cash provided by financing activities [3]	-0.7	1.1	-6.4	-4.7	-0.4	-1.3	-1.5
Change in liquid funds [1]+[2]+[3]	3.9	6.9	-3.5	-3.0	3.2	2.8	3.2
Effects of exchange-rate changes on cash	0.5	-1.4	0.5	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	18.7	24.2	21.2	18.1	21.3	24.1	27.3

Financial Ratios							
	2016	2017	2018	2019	2020e	2021e	2022e
Cash Flow							
FCF	4.6	5.8	6.1	2.8	3.6	4.1	4.7
Free Cash Flow / Sales	2.3 %	2.8 %	3.0 %	1.3 %	1.9 %	2.0 %	2.3 %
Free Cash Flow Potential	11.6	12.3	1.8	9.7	12.0	14.0	14.2
Free Cash Flow / Net Profit	78.4 %	124.3 %	685.7 %	163.8 %	102.9 %	91.4 %	93.3 %
Interest Received / Avg. Cash	5.9 %	6.9 %	8.7 %	7.2 %	2.5 %	2.3 %	2.1 %
Interest Paid / Avg. Debt	4.2 %	4.7 %	3.4 %	4.0 %	0.6 %	0.6 %	0.6 %
Management of Funds							
Investment ratio	10.8 %	7.5 %	8.8 %	9.7 %	13.5 %	13.1 %	12.7 %
Maint. Capex / Sales	2.4 %	2.3 %	2.4 %	2.3 %	2.5 %	2.4 %	2.4 %
Capex / Dep	125.8 %	81.2 %	104.2 %	73.9 %	115.6 %	113.0 %	113.0 %
Avg. Working Capital / Sales	9.4 %	9.3 %	8.6 %	7.7 %	8.1 %	7.9 %	7.9 %
Trade Debtors / Trade Creditors	178.9 %	174.2 %	135.7 %	124.4 %	129.6 %	129.6 %	129.6 %
Inventory Turnover	8.6 x	9.7 x	9.1 x	8.2 x	8.1 x	8.1 x	8.1 x
Receivables collection period (days)	34	35	34	32	33	33	33
Payables payment period (days)	40	40	50	52	53	53	53
Cash conversion cycle (Days)	36	32	24	24	25	25	25



COMMENT Published 27.05.2020

7



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
- 3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
- 4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Francotyp-Postalia	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000FPH9000.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.


Rating	Number of stocks	% of Universe
Buy	130	63
Hold	59	29
Sell	9	4
Rating suspended	7	3
Total	205	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	34	81
Hold	5	12
Sell	0	0
Rating suspended	3	7
Total	42	100

PRICE AND RATING HISTORY FRANCOTYP-POSTALIA AS OF 27.05.2020



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES Matthias Rode Head of Equities RESEARCH	+49 40 3282-2678 mrode@mmwarburg.com		
Head of Equities			
RESEARCH	illiode@illillwarburg.com		
Michael Heider	+49 40 309537-280	Eggert Kuls	+49 40 309537-256
Head of Research Henner Rüschmeier	mheider@warburg-research.com +49 40 309537-270	Engineering Andreas Pläsier	ekuls@warburg-research.com +49 40 309537-246
Head of Research	hrueschmeier@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Malte Schaumann	+49 40 309537-170
Jonas Blum	+49 40 309537-240	Technology Patrick Schmidt	mschaumann@warburg-research.com +49 40 309537-125
Telco, Construction	jblum@warburg-research.com	Leisure, Internet	pschmidt@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Felix Ellmann	+49 40 309537-120	Simon Stippig	+49 40 309537-265
Software, IT	fellmann@warburg-research.com	Real Estate	sstippig@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Cansu Tatar Cap. Goods, Engineering	+49 40 309537-248 ctatar@warburg-research.com
Marius Fuhrberg	+49 40 309537-185	Marc-René Tonn	+49 40 309537-259
Financial Services Mustafa Hidir	mfuhrberg@warburg-research.com +49 40 309537-230	Automobiles, Car Suppliers Robert-Jan van der Horst	mtonn@warburg-research.com +49 40 309537-290
Automobiles, Car Suppliers	mhidir@warburg-research.com	Technology	rvanderhorst@warburg-research.com
Ulrich Huwald	+49 40 309537-255	Andreas Wolf	+49 40 309537-140
Health Care, Pharma Philipp Kaiser	uhuwald@warburg-research.com +49 40 309537-260	Software, IT	awolf@warburg-research.com
Real Estate	pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257		
	tkleibauer@warburg-research.com		
INSTITUTIONAL EQUITY			
Marc Niemann Head of Equity Sales, Germany	+49 40 3282-2660 mniemann@mmwarburg.com	Tobias Hald United Kingdom	+49 40 3282-2695 thald@mmwarburg.com
Klaus Schilling	+49 40 3282-2664	Maximilian Martin	+49 69 5050-7413
Head of Equity Sales, Germany	kschilling@mmwarburg.com	Austria, Poland	mmartin@mmwarburg.com +49 69 5050-7414
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com	Christopher Seedorf Switzerland	cseedorf@mmwarburg.com
Lyubka Bogdanova	+49 69 5050-7411		
Ireland, Poland, Australia Jens Buchmüller	lbogdanova@mmwarburg.com +49 69 5050-7415		
Scandinavia, Austria	jbuchmueller@mmwarburg.com		
Alexander Eschweiler	+49 40 3282-2669	Sophie Hauer	+49 69 5050-7417
Germany, Luxembourg	aeschweiler@mmwarburg.com	Roadshow/Marketing	shauer@mmwarburg.com +49 40 3282-2694
Matthias Fritsch United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com	Juliane Niemann Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING			, -
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading	omerckel@mmwarburg.com	Sales Trading	mmagiera@mmwarburg.com
Elyaz Dust	+49 40 3282-2702	Bastian Quast	+49 40 3282-2701
Sales Trading Michael Ilgenstein	edust@mmwarburg.com +49 40 3282-2700	Sales Trading Jörg Treptow	bquast@mmwarburg.com +49 40 3282-2658
Sales Trading	milgenstein@mmwarburg.com	Sales Trading	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fou		investment Strategy	cjaspernette@mmwarburg.com
	research.mmwarburg.com/en/index.html	Thomson Reuters	www.thomsonreuters.com
Bloomberg	MMWA GO	Capital IQ	www.thomsomeuters.com www.capitaliq.com
FactSet	www.factset.com	op.w d	
For access please contact			
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com